Argenx stock advances on a broad business update

Argenx stock is in a broad update phase as the biotech continues to build around its immunology franchise and U.S. market presence.

Argenx (ISIN NL0010832176) remains a U.S.-relevant biotech name through its Nasdaq listing and its immunology-focused pipeline.

Business profile

The company is built around antibody-based medicines and a commercial footprint centered on severe autoimmune disease. That makes Argenx a pure-play immunology story rather than a diversified large-cap healthcare group.

U.S. market angle

For U.S. investors, the key frame is the company’s Nasdaq access and its exposure to the American biotech valuation cycle. In that sense, Argenx moves more like a growth-biotech peer than a traditional pharma cash-flow story.

Product focus

Its lead product is Vyvgart, the therapy most closely associated with the company’s commercial narrative and pipeline follow-through.

Trading context

Argenx stock trades on Nasdaq in U.S. dollars. The shares last changed hands at $0.00 as of July 12, 2026, 6:15 a.m. ET.

Argenx stock facts

• Company: Argenx SE
• ISIN: NL0010832176
• Ticker: ARGX
• Exchange: Nasdaq
• Sector / Industry: Healthcare / Biotechnology